IFN-dependent and IFN-independent pathways in SLE
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY/ABSTRACT Systemic lupus erythematosus (SLE) is characterized by increased expression of interferon (IFN)-induced genes, known as the IFN signature, pointing to IFNs as promising therapeutic targets in SLE. Disappointingly, only a subset of SLE patients who express the IFN signature have shown benefit in clinical trials targeting the type I IFN (IFN-I) pathway, and inhibiting IFN-II has completely failed to treat SLE. To date, there is no explanation for this puzzle. Our studies indicate that dysregulated IFN expression is not a unifying feature among patients with SLE, and that the IFN signature is not always analogous to increased levels of IFNs. Instead, based on IFN levels and the IFN signature, patients with SLE can be classified into at least three disease subsets of mechanistic relevance. One subset is distinguished by increased levels of IFN-I alone and is associated with cutaneous lupus. The second subset is linked to systemic disease and is associated with elevated levels of IFN- I in combination with IFN-II and IFN-III, indicating a synergistic effect of IFN types on disease severity. The third subset includes SLE patients whose IFN signature is not explained by IFNs, but rather by stimuli that mimic IFN signaling. Together, the proposed subsets provide novel insights into mechanisms of disease heterogeneity in SLE, as well as a rational explanation for the variable response in clinical trials targeting the IFN-I pathway, even among patients expressing the IFN signature. In this project, we will use unique cohorts of patients with cutaneous lupus and SLE, as well as state-of-the-art technologies, to examine the mechanisms that define clinical endotypes linked to IFN-I, as well as the identity of IFN-independent factors that mirror the induction of the IFN signature in a significant subset of patients with SLE. Our long-term goal is to apply this knowledge to develop precise mechanism-guided preventive and therapeutic interventions for SLE.
Grant Summary
IFN-dependent and IFN-independent pathways in SLE is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $748K for university, nonprofit, healthcare org. Applications are due 2031-07-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $748K
2031-07-31
- 1Confirm your organization is eligible for IFN-dependent and IFN-independent pathways in SLE from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
IFN-dependent and IFN-independent pathways in SLE: Frequently Asked Questions
Who is eligible for the IFN-dependent and IFN-independent pathways in SLE?
IFN-dependent and IFN-independent pathways in SLE is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the IFN-dependent and IFN-independent pathways in SLE provide?
IFN-dependent and IFN-independent pathways in SLE provides up to $748K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the IFN-dependent and IFN-independent pathways in SLE deadline?
Applications for IFN-dependent and IFN-independent pathways in SLE are due 2031-07-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the IFN-dependent and IFN-independent pathways in SLE?
To apply for IFN-dependent and IFN-independent pathways in SLE, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.